ALIA SANTÉ
Redefining Health Data through Synthetic Intelligence

ALIA SANTÉ is reshaping the future of health data with synthetic datasets that are clinically meaningful, statistically robust, and fully compliant with the world’s strictest privacy regulations. Combining advanced generative modelling with explicit clinical knowledge empowers pharmaceutical firms, hospitals, researchers, and digital health innovators to unlock the full value of health data, without exposing patient information.

The company’s generative models result from several years of research and development, co-funded by the European Union and BPI France. In 2022, ALIA SANTÉ conducted a comprehensive review of synthetic data technologies, identifying significant performance gaps and barriers to their application in healthcare. Over the past three years, it has developed over twenty neural networks capable of understanding and generating health data across multiple modalities. These include medical imaging such as CT scans and MRIs, structured datasets like electronic health records, and complex time-series data capturing vital signs and longitudinal patient trajectories.

“Our models are transforming clinical research, enabling faster breakthroughs, broader patient representation, and a new era of cost-efficient innovation,” says Sylvain Francoise Dal-Mas, chairman of ALIA SANTÉ.

Clinically Meaningful Synthetic Data

What distinguishes the company is its ability to generate synthetic datasets that preserve clinical nuance. ALIA SANTÉ’s platform can simulate medically plausible rare conditions, replicate care pathways in realistic detail, and reflect population-level health trends. The datasets are statistically consistent and clinically meaningful, supporting AI development, clinical trials, and digital health innovation.

The benefits are substantial. Researchers can expand cohorts, strengthening statistical power and include underrepresented subgroups. Digital health developers accelerate the training and testing of AI models while reducing bias caused by incomplete samples. Clinical teams prepare or supplement trials and even create synthetic control arms where real-world data is limited.

Access to ALIA SANTÉ’s platform is flexible and secure. In its SaaS mode, users upload pseudonymised data through a secure interface, select a relevant generative model, and generate ready-to-use synthetic datasets in minutes, accompanied by automated quality and compliance reports.

For more complex use cases, such as rare diseases or highly heterogeneous datasets, ALIA SANTÉ works closely with clients to calibrate models and tailor outputs. And for organisations with strict data sovereignty or security requirements, the platform can be deployed on-premise, ensuring sensitive data never leaves the client’s environment.

Where Performance Meets Patient Protection

The platform reproduces the richness of healthcare data across diverse sources, including structured hospital records, laboratory results, physician notes, imaging, and longitudinal time series. Combining generative models with clinical protocols, drug interaction knowledge, and reference datasets produces synthetic data that is realistic in time, credible in practice, and robust in statistics.

Clients consistently emphasise three key types of positive feedback. This includes the realism of data that reflects genuine care pathways, even in rare conditions; the privacy-first framework, which fosters innovation while ensuring compliance; and the expert support of ALIA SANTÉ’s teams, who provide responsive and practical guidance from setup to deployment.

A recent collaboration illustrates this impact. A pharmaceutical company conducting a Phase III trial faced slow recruitment and insufficient statistical power, particularly in underrepresented subgroups. By generating a synthetic extension cohort calibrated to real trial data, the company increased its adequate sample size by 20 per cent, achieved statistical significance in key subgroups, shortened study timelines and maintained full regulatory compliance. Synthetic data did not replace the clinical trial; it enhanced it, delivering results faster, safer, and smarter.

What sets ALIA SANTÉ apart is its technological sophistication and ethical commitment to health innovation. Its mission is to reconcile innovation with trust and performance with patient protection. As health data becomes increasingly vital yet sensitive, ALIA SANTÉ offers a secure and responsible alternative: synthetic data that is useful, credible, and sovereign. More than just data generation, it unlocks the full potential of health innovation while keeping patient protection at the heart of progress.